Healthcare
Cybin Inc.(CYBN)
Live Price
Offline$4.85
+3.85% today
1Y Change
-41.28%
Window
Jun 25, 2025 β Jun 23, 2026
- Market Cap
- $130.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +93.6%
- Dividend Yield
- 0.0%
Coverage: 249 bars Β· Jun 25, 2025 β Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Cybin Inc. (CYBN) is a Healthcare stock with a market cap of $130.00M and listed on NYSE. The stock last traded around $4.85 and down 41.3% across the available one-year price window (Jun 25, 2025 β Jun 23, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +93.6%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +93.6%, free cash flow -48.3% with operating margin 0.0% and ROIC -50.7%. Stock Foundry combines CYBN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report landed above expectations
2026 was reported on Feb 9, 2026 with an EPS surprise of +28.3%.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +93.6%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -2.6% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Feb 9, 2026 | +28.3% | +1.4% | +7.0% | -9.2% |
2025 Nov 13, 2025 | -87.8% | -0.2% | -1.5% | +12.5% |
2025 Aug 13, 2025 | -115.7% | -5.7% | -13.2% | -20.9% |
Benchmark Edge
CYBN vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CYBN
β
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CYBN Max Drawdown
-57.00%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CYBN and SPY.
Company Overview
Cybin Inc.
NYSE
Cybin Inc. is a biotechnology company specializing in advancing psychedelic therapeutics. It focuses on developing drug candidates based on psilocybin and other psychoactive compounds for mental health applications. Cybin aims to innovate new formulations and delivery methods to enhance efficacy and safety profiles. The company operates within the rapidly evolving biopharmaceutical sector, targeting neuropsychiatric disorders such as depression, anxiety, and substance use disorders. Cybinβs role in the financial markets represents the growing investor interest in the mental health and psychedelics space, reflecting broader trends in pharmaceutical innovation and alternative medicine research. Its stock is listed on multiple exchanges, including a secondary listing on the Berlin Stock Exchange, which expands its access to European investors and highlights its international presence in capital markets.
- Leadership
- Mr. Eric So L.L.B.
- Employees
- 50
- Street Address
- 100 King Street West, Suite 5600
- Mailing
- Toronto, ON, M5X 1C9
- Region
- Toronto, ON, Canada
- Last Updated
- May 10, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- β
- EV/EBITDA
- 0.5
- Price/Sales
- β
- Price/Book
- 0.8
Growth
- Revenue
- 0.0%
- EPS
- +93.6%
- Free Cash Flow
- -48.3%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -61.5%
- ROIC
- -50.7%
Balance Sheet
- Debt/Equity
- β
- Current Ratio
- 13.78
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.